Study Title: A pilot study on clinical pharmacokinetics and preclinical pharmacodynamics of (+)-epicatechin on cardiometabolic endpoints
Citation: Moreno-Ulloa et al., 2018. Food & Function
What the Study Found: This pilot study evaluated (+)-epicatechin in healthy and pre-diabetic adults and found a favorable pharmacokinetic and safety profile after single-dose and 7-day dosing. In a mouse model of diet-induced obesity and insulin resistance, (+)-epicatechin dose-dependently improved metabolism-related endpoints including weight gain, glucose, cholesterol, and triglycerides, while (+)-catechin did not show the same effects.
What this means in real life: This study suggests that (+)-epicatechin may influence cardiometabolic health through targeted effects on metabolism rather than broad antioxidant activity alone. It also supports the idea that cellular energy regulation and metabolic signaling are tightly connected to outcomes like blood sugar, lipids, and weight control.
Related Content:
- Want to understand how cellular energy connects to cardiovascular and metabolic risk? → 4 Risk Factors for Heart Disease and How to Improve Them Through a Better Understanding of Cellular Energy
- Curious how mitochondrial dysfunction shows up in real metabolic conditions tied to fat accumulation and insulin resistance? → Mitochondrial Health and Fatty Liver
- Want to see how epicatechin is discussed in relation to cellular energy and mitochondrial support? → Mitozz, (-)-Epicatechin and “Mitochondrial Support”